Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002553927 | SCV001227551 | pathogenic | not provided | 2019-12-04 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). This variant results in the deletion of part of exon 5 (c.556-3_562del) of the FH gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant has not been reported in the literature in individuals with FH-related conditions. For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in FH are known to be pathogenic (PMID: 11865300, 21398687). This variant disrupts the p.Ser186 amino acid residue in FH. Other variant that disrupts this residue has been determined to be pathogenic (PMID: 31444830, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. |